Publication & Citation Trends
Publications
0 total
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cited by 50
Semantic Scholar
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. OA
Cited by 424
Semantic Scholar
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Cited by 823
Semantic Scholar
Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).
Cited by 5
Semantic Scholar
Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
Cited by 39
Semantic Scholar
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. OA
Cited by 1,209
Semantic Scholar
Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). OA
Cited by 70
Semantic Scholar
TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells OA
Cited by 4,308
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(17)
HER2/EGFR in Cancer Research
(10)
Cancer Treatment and Pharmacology
(10)
Breast Lesions and Carcinomas
(6)
Cancer Immunotherapy and Biomarkers
(3)
Affiliations
The University of Texas MD Anderson Cancer Center
Brown University
Institut Gustave Roussy
Dubai Hospital